Xencor Inc. (XNCR)
NASDAQ: XNCR
· Real-Time Price · USD
11.77
-0.05 (-0.42%)
At close: Oct 03, 2025, 3:59 PM
11.77
0.00%
After-hours: Oct 03, 2025, 05:45 PM EDT
-0.42% (1D)
| Bid | 8.72 |
| Market Cap | 839.47M |
| Revenue (ttm) | 164.15M |
| Net Income (ttm) | -177.87M |
| EPS (ttm) | -2.36 |
| PE Ratio (ttm) | -4.99 |
| Forward PE | -4.1 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 15 |
| Volume | 494,874 |
| Avg. Volume (20D) | 1,012,136.5 |
| Open | 11.96 |
| Previous Close | 11.82 |
| Day's Range | 11.71 - 12.12 |
| 52-Week Range | 6.92 - 27.24 |
| Beta | 0.96 |
| Ex-Dividend Date | n/a |
About XNCR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol XNCR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for XNCR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsXencor Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
-21.08%
Shares of vaccine and gene therapy stocks are trad...
Unlock content with
Pro Subscription
2 weeks ago · seekingalpha.com
Xencor: Bispecific Antibody Program Takes Shape With Q4 Data ReleaseXencor remains a "Strong Buy" rating due to progress in its bispecific and monospecific antibody pipeline targeting inflammatory disorders and cancer. XNCR's XmAb942 anti-TL1A antibody is advancing to...
